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Abstract
Treatment with non-steroidal anti-inflammatory drugs (NSAIDs)
is hampered by gastrointestinal ulcer complications, such as
ulcer bleeding and perforation. The efficacy of proton-pump
inhibitors in the primary prevention of ulcer complications arising
from the use of NSAIDs remains unproven. Selective
cyclooxygenase-2 (COX-2) inhibitors reduce the risk for ulcer
complications, but not completely in high-risk patients. This
study determines which patients are especially at risk for NSAID
ulcer complications and investigates the effectiveness of
different preventive strategies in daily clinical practice. With the
use of a nested case-control design, a large cohort of NSAID
users was followed for 26 months. Cases were patients with
NSAID ulcer complications necessitating hospitalisation;
matched controls were selected from the remaining cohort of
NSAID users who did not have NSAID ulcer complications.
During the observational period, 104 incident cases were
identified from a cohort of 51,903 NSAID users with 10,402
patient years of NSAID exposure (incidence 1% per year of
NSAID use, age at diagnosis 70.4 ± 16.7 years (mean ± SD),
55.8% women), and 284 matched controls. Cases were
characterised by serious, especially cardiovascular, co-
morbidity. In-hospital mortality associated with NSAID ulcer
complications was 10.6% (incidence 21.2 per 100,000 NSAID
users). Concomitant proton-pump inhibitors (but not selective
COX-2 inhibitors) were associated with a reduced risk for
NSAID ulcer complications (the adjusted odds ratio 0.33; 95%
confidence interval 0.17 to 0.67; p = 0.002). Especially at risk
for NSAID ulcer complications are elderly patients with
cardiovascular co-morbidity. Proton-pump inhibitors are
associated with a reduced risk for NSAID ulcer complications.
Introduction
Treatment with non-steroidal anti-inflammatory drugs
(NSAIDs) is known to be complicated by gastrointestinal tox-
icity. NSAIDs impair prostaglandin-dependent gastric mucosal
protective mechanisms. When these defences have been
breached, a second wave of injury caused by luminal gastric
acid may facilitate deeper ulceration [1]. Prevention of gas-
troduodenal ulcers attributable to the use of NSAIDs may tar-
get the inhibition of gastric acid secretion with histamine-2
receptor antagonists (H2RAs) or proton-pump inhibitors
(PPIs). Alternatively, locally depleted endogenous cytoprotec-
tive prostaglandins may be replaced by the administration of
prostaglandin E1  analogues, such as misoprostol. Several
studies have evaluated and compared these strategies [2].
COX = cyclooxygenase; H2RAs = histamine-2 receptor antagonists; INR = international normalized ratio; NSAIDs = non-steroidal anti-inflammatory 
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High-dose misoprostol is effective in the primary prevention of
endoscopic NSAID ulcers and also NSAID ulcer complica-
tions, such as bleeding and perforation, but is often poorly tol-
erated because of diarrhoea and abdominal discomfort [3].
Elevation of the intragastric pH by PPIs and high-dose H2RAs
reduces the risk of endoscopic NSAID ulcers [2]. In direct
comparison, PPIs show an efficacy comparable to that of mis-
oprostol, but they are better tolerated [4]. Furthermore, PPIs
are more effective in the prevention of NSAID ulcers than low-
dose H2RAs [5]. However, the efficacy of PPIs and H2RAs in
the primary prevention of clinically relevant endpoints, such as
bleeding and perforated NSAID ulcers, remains unproven.
The discovery of the isoenzymes cyclooxygenase (COX)-1
and COX-2 made it possible to develop highly selective COX-
2 inhibitors [6]. The hypothesis is that COX-1 is expressed
constitutively and regulates normal physiology, such as the
maintenance of gastric mucosal integrity. Conversely, COX-2
is expressed selectively after exposure to inflammatory media-
tors or trauma, and has a role in inflammation and pain [7]. In
randomised controlled clinical trials, selective COX-2 inhibi-
tors have demonstrated a decreased risk for NSAID ulcers and
also ulcer complications [8-11]. Furthermore, in elderly
patients with a recent history of bleeding NSAID ulcers, sec-
ondary prevention (preventing recurrent bleeding) with a
selective COX-2 inhibitor seems comparable to combining a
non-selective NSAID with a PPI, although in that study the
number of cases was small and neither strategy provided ade-
quate protection [12].
Because of their relatively low incidence, severe gastrointesti-
nal ulcer complications such as bleeding and perforated
ulcers can be evaluated most effectively in large observational
studies [13]. Randomised controlled clinical trials are
designed to evaluate the efficacy of a certain strategy, and
despite including thousands of patients they may fail to detect
infrequent or long-term complications or side effects. Further-
more, rigorous inclusion and exclusion criteria are maintained,
and those at high risk for drug side effects or complications
are usually excluded. Conversely, in daily clinical practice, it is
especially at-risk patients who are likely to be treated with
these new strategies under the assumption of safe, evidence-
based pharmacotherapy. Although observational studies are
subject to possible bias, they best reflect daily clinical practice
and are well suited to study infrequent and long-term compli-
cations and side effects. Therefore, to determine the charac-
teristics of patients who are especially at risk for serious
NSAID ulcer complications and to compare the effectiveness
of different preventive strategies in daily clinical practice, we
conducted a large nested case-control study.
Materials and methods
This nested case-control study was performed within the gov-
ernment-initiated healthcare region of the city of Enschede in
The Netherlands. On 31 December 2003 the population con-
sisted of 152,989 persons living in a well-defined geographi-
cally isolated area largely bordering on Germany. All in-patient
healthcare is provided by a single teaching hospital, supplied
with all diagnostic and therapeutic facilities. All drug prescrip-
tions are registered in electronic prescription records of 14
local pharmacies. Most drugs, including NSAIDs, are provided
by the patient's own pharmacy, directly reimbursed by the
healthcare system. A cohort of NSAID users can be identified
continuously from the electronic prescription records.
Serious NSAID ulcer complications were defined as ulcera-
tions of the stomach or proximal duodenum causing perfora-
tion, obstruction or bleeding that occurred during the use of
NSAIDs, necessitating hospitalisation of the patient.
Selection of cases
During a prospective 26-month observational period (Novem-
ber 2001 to December 2003), we identified all consecutive
NSAID users who were hospitalised with serious NSAID ulcer
complications. Most patients were identified during endos-
copy or abdominal surgery. A few patients were identified on
the basis of a clinical presentation of upper gastrointestinal
bleeding alone, with haematemesis or melaena, if no further
diagnostic procedure was performed because of co-morbidity
or advanced age. In some of these patients the diagnosis was
confirmed during autopsy. Patients were included in the study
if they used NSAIDs (including selective COX-2 inhibitors) at
the time of diagnosis of a gastroduodenal ulcer. Aspirin in high
dosage (more than 100 mg daily) was considered to be a
NSAID. As soon as possible after the diagnosis, patients were
given a questionnaire on their sociodemographic characteris-
tics, actual and recent medication, co-morbidity and medical
history. The questionnaire contained specific items on the use
of NSAIDs, aspirin, anticoagulants, gastroprotective drugs,
and steroids, and also on the history of gastroduodenal events.
For verification of the questionnaires, we reviewed the medical
charts of all cases, as well as reports on endoscopy, surgery
and pathology. Medication use before and during hospitalisa-
tion, as reported by the patient, was verified by reviewing pre-
scription registrations provided by the in-hospital and
community-based pharmacies. Patients were interviewed by
one of the authors (HV) if ambiguities were encountered in the
questionnaires or during verification.
Patients were excluded if they reported not having used
NSAIDs, if endoscopy, surgery or autopsy did not reveal gas-
troduodenal ulcers, if ambiguities remained despite interview-
ing the patient, if a malignancy of the stomach was diagnosed
or if another reason for upper intestinal bleeding (such as
esophagogastric varices, arteriovenous malformations, diffuse
gastritis or Mallory–Weiss tears) was diagnosed.
Selection of controls
Matched controls were selected from the remaining cohort of
NSAID users. For selecting controls, index dates were definedAvailable online http://arthritis-research.com/content/9/3/R52
Page 3 of 8
(page number not for citation purposes)
as the day on which an NSAID ulcer was diagnosed in each of
the cases. Controls were frequency-matched on sex and age,
and had to be using NSAIDs (including selective COX-2 inhib-
itors) on the index date. Selected controls were asked to com-
plete the same questionnaire as the cases. Medication use as
reported by the controls was verified by reviewing prescription
databases. Controls were interviewed if ambiguities were
encountered in the questionnaires or during verification. All
non-responders were sent a second identical questionnaire.
Finally, a random sample of non-responders was telephoned
to detect bias in non-responding.
Statistical analysis
In univariate analyses, potential confounding continuous varia-
bles were analysed with Student's t-test and nominal data
were analysed with Pearson χ2 tests or Fisher's exact tests for
small numbers. Multivariate analyses were performed by using
logistic regression with NSAID ulcers as the dependent varia-
ble. A full model consisting of all significant and other likely
causational variables was reduced stepwise to a parsimonious
model. All p  values were two-sided, and p  ≤ 0.05 was
regarded as significant. All analyses were performed with
SPSS for Windows, version 12.0.1 (SPSS, Chicago, IL, USA).
The study was approved by the Medical Ethics Reviewing
Committee of the Medisch Spectrum Twente Hospital. There
were no external sources of funding or study sponsors.
Results
Over the 26-month prospective observational period the
cohort of NSAID users contained 51,903 NSAID users with
10,402 patient years of NSAID exposure. From this cohort,
104 cases were hospitalised with serious NSAID ulcer com-
plications. Because of the geographically isolated position,
referral to other hospitals, especially for acute gastrointestinal
events, is extremely rare. Therefore, in this population the inci-
dence of hospitalisation due to serious NSAID ulcer complica-
tions can be reliably calculated at 1% per year of NSAID use.
Table 1 shows demographic characteristics and co-morbidi-
ties. The typical case is an elderly patient, age at diagnosis
70.4 ± 16.7 years (mean ± SD; range 22 to 98 years), 55.8%
were female. Many patients reported concurrent disease or
previous medical events suggesting serious, especially cardi-
ovascular, co-morbidity. This self-reported co-morbidity was
supported by the concomitant medication used (Table 2). The
104 cases together used 12 different NSAIDs (Table 2). The
duration of NSAID use before the gastrointestinal event varied;
the median was 1.13 months (interquartile range 10 days to
12 months). Most patients did not exceed their prescribed
maximum daily dose. However, occasional use of more than
one NSAID simultaneously was reported by 12 patients
(11.5%).
In most cases (80 patients, 76.9%), serious NSAID ulcer com-
plication was the reason for presentation and hospitalisation.
In the remainder a serious NSAID ulcer complication took
place during hospitalisation for another reason. Characteris-
tics of the gastrointestinal events are presented in Table 3. No
diagnostic procedure was performed in only six (5.8%)
patients, because of co-morbidity or advanced age. The mean
haemoglobin level at presentation was 6.1 ± 1.9 mmol/l (mean
± SD; range 1.8 to 9.8). In those using coumarin, the interna-
tional normalized ratio (INR) at presentation was 4.87 ± 1.41
(mean ± SD) but the mean haemoglobin level at presentation
did not differ from that in patients not taking coumarin, and nei-
ther did the number of units of blood administered during
hospitalisation.
Mortality due to serious NSAID ulcer complications was high:
11 patients (10.6%) died in hospital, and another 4 (3.8%)
died within 3 months of the diagnosis. The incidence of in-hos-
pital mortality due to serious NSAID ulcer complications can
be calculated at 21.2 per 100,000 NSAID users.
For 104 cases, 757 controls were selected from the remaining
cohort of NSAID users. On receiving the first questionnaire
225 controls responded, of whom 203 were included. On
receiving a second questionnaire, a further 123 responded, of
whom 81 were included. From the 64 excluded responders,
18 questionnaires were returned by someone other than the
selected control, 15 denied taking NSAIDs, 17 refused, 1 had
been hospitalised in a psychiatric hospital, 1 was a case who
had already been included as such, and for 12 controls rela-
tives informed us that the selected person had died. In the
group of 20 randomly selected non-responders who were tel-
ephoned, no bias for non-responding was found.
In total 284 controls, frequency matched for age and sex, with
NSAID use on the index date were included. Demographic
characteristics, co-morbidities and current medication use are
summarised in Tables 1 and 2. The mean age was slightly
lower for the controls than for the cases because insufficient
numbers of controls could be found for some of the extremely
elderly cases.
Statistical results
In univariate analysis, cases and controls differ significantly
with regard to body mass index, smoking habits, marital status,
medical history of heart failure, myocardial infarction, stroke
and renal insufficiency (Table 1). Significant differences in
medication use were found for PPIs, coumarin, low-molecular-
mass heparin, analgesics, diuretics, angiotensin-converting-
enzyme inhibitors, oral glucose-lowering drugs, benzodi-
azepines and disease-modifying anti-rheumatic drugs (Table
2).
Concomitant use of PPIs was significantly higher in the con-
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0.005). Use of selective COX-2 inhibitors was comparable
(cases 16.4%; controls 17.6%; p = 0.77). Use of the prefer-
ential COX-2 inhibitor meloxicam differed, but not significantly,
and numbers were small (cases 1%; controls 4.2%; p = 0.20).
A full logistic regression model of all significant and other likely
causational variables was reduced stepwise to a parsimonious
model, finally containing concomitant use of PPIs, low-molec-
ular-mass heparin, acetaminophen, coumarin, and history of
heart failure (Table 4). Use of selective COX-2 inhibitors was
not associated with a significantly reduced risk for serious
NSAID ulcer complications (p = 0.74); neither was the use of
preferential COX-2 inhibitors (p = 0.22). Concomitant use of
PPIs was associated with a significantly reduced risk for seri-
ous NSAID ulcer complications (adjusted odds ratio 0.33;
95% confidence interval 0.17 to 0.67; p = 0.002).
In a post hoc subgroup analysis of selective COX-2 inhibitor
users, there were no significant differences in concomitant use
of low-dose aspirin (8 cases (47%); 19 controls (38%); p =
0.51), non-selective NSAIDs (3 cases (18%); 10 controls
(20%); p = 0.83) or PPIs (3 cases (18%); 17 controls (34%);
p = 0.20); neither were there significant differences in con-
comitant use of coumarin, heparin, steroids or high-dose
H2RAs or in ulcer history.
Furthermore, among those taking selective COX-2 inhibitors,
cases and controls did not differ significantly with regard to the
number of risk factors for NSAID-associated gastropathy, sug-
gesting comparable risk profiles. Similarly, in a post hoc sub-
group analysis for those taking either proton-pump inhibitors
or high-dose H2RAs, cases and controls again did not differ
significantly with regard to the number of risk factors for
NSAID-associated gastropathy.
In six patients no diagnostic procedure was performed
because of co-morbidity or advanced age. In a post hoc anal-
ysis these patients with probable NSAID ulcers were com-
pared with the 98 patients with definite NSAID ulcers.
Significant differences between patients with probable or def-
inite NSAID ulcers were age (mean 87.3 and 69.4 years,
respectively; p = 0.01), medical history of diabetes mellitus,
Table 1
Sociodemographic characteristics and co-morbidities for cases and controls
Characteristic Cases (n = 104) Controls (n = 284) OR 95% CI p
Age at diagnosis (years) 70.4 ± 16.7 67.1 ± 14.3
Female sex 58 (55.8) 163 (57.4)
Body mass index (kg/m2) 24.7 ± 4.7 26.7 ± 4.6 - - 0.001
Smoking 28 (26.9) 51 (18) 1.96 1.15–3.37 0.01
Alcohol (glasses per week) 9.6 ± 33.2 6.2 ± 8.6 - - 0.12
Coffee (cups per week) 18.9 ± 20.6 22.8 ± 13.8 - - 0.06
Education low vocational or less 39 (56.5) 176 (64.0) 0.73 0.43–1.25 0.25
Married 42 (46.7) 166 (59.3) 0.60 0.37–0.97 0.04
Medical history
Hypertension 30 (28.8) 95 (33.5) 0.81 0.49–1.32 0.39
Heart failure 26 (25.0) 32 (11.3) 2.63 1.48–4.67 0.001
COPD 25 (24.0) 57 (20.1) 1.26 0.74–2.15 0.40
Myocardial infarction 20 (19.2) 32 (11.3) 1.88 1.02–3.45 0.04
Stroke 18 (17.3) 28 (9.9) 1.91 1.01–3.63 0.04
Heart rhythm disturbance 18 (17.3) 52 (18.3) 0.93 0.52–1.69 0.82
Diabetes mellitus 16 (15.4) 33 (11.6) 1.38 0.73–2.64 0.32
Anaemia 16 (15.4) 32 (11.3) 1.43 0.75–2.74 0.28
Renal insufficiency 16 (15.4) 15 (5.3) 3.26 1.55–6.86 0.001
Previous gastrointestinal ulcers 16 (15.4) 33 (11.7) 1.37 0.72–2.60 0.34
Malignancy 15 (14.4) 26 (9.2) 1.67 0.85–3.30 0.14
Rheumatoid disease, including OA 42 (40.4) 97 (34.2) 1.31 0.82–2.07 0.26
Scores are means ± SD or number of patients (percentage). OR, unadjusted odds ratio; CI, confidence interval; COPD, chronic obstructive 
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Table 2
NSAIDs and concurrent medication in use at the time of the gastrointestinal event
Medication Cases (n = 104) Controls (n = 284) OR 95% CI p
Non-selective NSAIDs
Indometacin 3 (2.9) 4 (1.4) 2.08 0.46–9.45 0.39
Naproxen 10 (9.6) 14 (4.9) 2.05 0.88–4.78 0.09
Diclofenac 44 (42.3) 108 (38.0) 1.20 0.76–1.89 0.44
Diclofenac–misoprostol 8 (7.7) 19 (6.7) 1.16 0.49–2.74 0.73
Other NSAIDs 3 (2.9) 8 (2.8) 1.03 0.27–3.94 1.00
Ibuprofen 16 (15.4) 69 (24.3) 0.57 0.31–1.03 0.06
High-dose aspirin (>100 mg/day) 2 (1.9) 0 (0.0) - - 0.07
Selective NSAIDs
Rofecoxib 16 (15.4) 42 (14.8) 1.05 0.56–1.96 0.88
Celecoxib 1 (1.0) 8 (2.8) 0.34 0.04–2.71 0.46
Meloxicam 1 (1.0) 12 (4.2) 0.22 0.03–1.71 0.20
Gastroprotective drugs
Proton-pump inhibitors 14 (13.5) 77 (27.1) 0.42 0.23–0.78 0.005
H2RAs 4 (3.8) 9 (3.2) 1.22 0.37–4.06 0.74
Misoprostol 8 (7.7) 20 (7.0) 1.10 0.47–2.58 0.83
Additional risk factors
High-dose NSAID 11 (10.6) 17 (6.0) 1.86 0.84–4.11 0.12
More than one NSAID 12 (11.5) 54 (19.0) 0.56 0.28–1.09 0.08
Low-dose aspirin (≤ 100 mg/day) 32 (30.8) 69 (24.3) 1.39 0.84–2.28 0.20
Clopidogrel/dipyridamole 5 (4.8) 9 (3.2) 1.54 0.51–4.72 0.54
Coumarin 14 (13.5) 19 (6.7) 2.17 1.05–4.51 0.04
Low-molecular-mass heparin 13 (12.5) 2 (0.7) 20.14 4.46–90.94 <0.001
SSRIs 6 (5.8) 9 (3.2) 1.87 0.65–5.39 0.24
Corticosteroids 14 (13.5) 32 (11.3) 1.23 0.63–2.40 0.55
Analgesics
Acetaminophen 45 (43.3) 54 (19.0) 3.25 1.99–5.29 <0.001
Tramadol 12 (11.5) 6 (2.1) 6.04 2.21–16.56 <0.001
Morphine 6 (5.8) 2 (0.7) 8.63 1.71–43.48 0.006
Cardiovascular drugs
Diuretics 34 (32.7) 57 (20.1) 1.93 1.17–3.20 0.009
ACE inhibitors 24 (23.1) 32 (11.3) 2.36 1.32–4.25 0.003
Digoxin 8 (7.8) 11 (3.9) 2.09 0.82–5.35 0.12
Beta-blockers 22 (21.2) 64 (22.5) 0.92 0.53–1.59 0.77
Nitrates 8 (7.7) 26 (9.2) 0.83 0.36–1.89 0.65
Calcium-channel blockers 10 (9.6) 35 (12.3) 0.76 0.36–1.59 0.46
Lipid-lowering drugs 9 (8.7) 38 (13.4) 0.61 0.29–1.32 0.21
Oral glucose-lowering drugs 12 (11.5) 15 (5.3) 2.34 1.06–5.18 0.03
Benzodiazepines 34 (32.7) 65 (22.9) 1.64 0.99–2.68 0.05
Inhalator therapy 22 (21.2) 56 (19.7) 1.09 0.63–1.90 0.76
DMARDs 14 (13.5) 20 (7.0) 2.05 0.99–4.23 0.05
Scores are number of patients (percentage). NSAIDs, non-steroidal anti-inflammatory drugs; OR, unadjusted odds ratio; CI, confidence interval; 
H2RAs, histamine-2 receptor antagonists; SSRIs, selective serotonin re-uptake inhibitors; ACE, angiotensin-converting enzyme; DMARDs, 
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chronic obstructive pulmonary disease and in-hospital mortal-
ity (66.7% and 7.1%, respectively; p  = 0.001). Excluding
these patients with probable NSAID ulcers from the cases did
not significantly change the results of the univariate or multivar-
iate analyses.
In 24 patients, serious NSAID ulcer complications occurred in
hospital. These patients were compared with the 80 patients
who presented with NSAID ulcer complications. Significant
differences between in-hospital or presenting patients were
sex (37.5% and 61.3% female, respectively; p = 0.04), ulcer
history (29.2% and 11.3%, respectively; p = 0.03), medical
history of a malignancy, diabetes mellitus, use of oral glucose-
lowering drugs and use of low-molecular-mass heparin
(45.5% and 3.8%, respectively; p < 0.001). Exclusion of these
in-hospital patients from the cases resulted in a significant
change in the univariate analyses for use of oral glucose-low-
ering drugs (cases 6.3%; controls 5.3%; p = 0.74) and for use
of low molecular mass heparin (cases 3.8%; controls 0.7%; p
= 0.04). The results of the multivariate analysis also changed
(Table 5).
Discussion
In this nested case-control study, the concomitant use of pro-
ton-pump inhibitors was associated with a two-thirds reduc-
tion in the risk for serious NSAID ulcer complications. The
efficacy of PPIs in the primary prevention of NSAID-associated
gastropathy has so far only been proven for subjective symp-
toms and surrogate endpoints, such as dyspepsia and endo-
scopic ulcers, and in the secondary prevention of serious
NSAID ulcer complications, PPIs do not seem to prevent
recurrence [12,14,15]. Our data suggest that PPIs may be
effective in the primary prevention of clinically relevant bleed-
ing and perforated NSAID ulcers, confirming other recent
observational studies [16-18]. However, randomised control-
led trials powered on these hard endpoints need to be con-
ducted to prove efficacy.
It is noteworthy that in this study the use of selective COX-2
inhibitors was not associated with protection for serious
NSAID ulcer complications. Lack of protection from selective
COX-2 inhibitors could not be explained by confounders such
as concomitant use of aspirin, coumarin, heparin or steroids or
by ulcer history. Previous studies demonstrating the efficacy of
selective COX-2 inhibitors in the primary prevention of NSAID
ulcer complications largely excluded high-risk patients,
Table 3
Characteristics of the gastrointestinal event attributable to use 
of non-steroidal anti-inflammatory drugs
Characteristic Number (percentage)
Clinical presentation
Melaena 65 (62.5)
Haematemesis 28 (26.9)
Perforation 12 (11.5)
Stomach pain 21 (20.2)
Collapse 16 (15.4)
No previous stomach 
complaints
57 (54.8)
Ulcer location
Gastric 53 (51.0)
Duodenal 34 (32.7)
Both gastric and duodenal 11 (10.6)
No diagnostic procedure 
performed
6 (5.7)
Ulcer perforation 14 (13.5)
Helicobacter pylori
Positive 21 (20.2)
Negative 45 (43.3)
Not tested 38 (36.5)
The total number of patients was 104.
Table 4
Multivariate analysis of significant variables and other likely 
causational variables for serious NSAID ulcer complications
Predictor Adjusted OR 95% CI p
Proton-pump 
inhibitors
0.33 0.17–0.67 0.002
Coumarin 2.09 0.93–4.70 0.075
Heart failure 2.44 1.28–4.66 0.007
Acetaminophen 2.80 1.64–4.79 <0.001
Low-molecular-
mass heparin
17.33 3.71–80.95 <0.001
Serious non-steroidal anti-inflammatory drug (NSAID) ulcer 
complication was the dependent variable. Only variables from the 
final parsimonious model are shown. OR, odds ratio; CI, confidence 
interval.
Table 5
Multivariate analysis after exclusion of patients with in-
hospital NSAID ulcer complications
Predictor Adjusted OR 95% CI p
Proton-pump inhibitors 0.31 0.15–0.66 0.002
Coumarin 2.38 1.03–5.48 0.04
Heart failure 2.10 1.04–4.21 0.04
Acetaminophen 2.47 1.39–4.39 0.002
Low-molecular-mass heparin 6.06 0.91–40.60 0.06
Serious non-steroidal anti-inflammatory drug (NSAID) ulcer 
complication was the dependent variable. Only variables from the 
final parsimonious model are shown. OR, odds ratio; CI, confidence 
interval.Available online http://arthritis-research.com/content/9/3/R52
Page 7 of 8
(page number not for citation purposes)
whereas in high-risk patients selective COX-2 inhibitors may
fail to prevent the recurrence of NSAID ulcer bleeding
[12,14,15]. Although neither selective COX-2 inhibitors nor
concomitant PPIs seem to be entirely effective in preventing
the recurrence of ulcer complications, our data suggest that
PPIs may be superior to selective COX-2 inhibitors in the pri-
mary prevention of NSAID ulcer complications.
Cases used coumarin more often than controls (adjusted odds
ratio 2.09; 95% confidence interval 0.93 to 4.70; p = 0.075).
Furthermore, in those cases using coumarin, the mean INR at
presentation was 4.87 ± 1.41 (mean ± SD) and one-third (5
patients) had an INR greater than 6.5. Although no INR was
measured in the controls, it is possible that this elevated INR
contributed to these patients developing serious NSAID ulcer
bleeding.
Cases used low-molecular-mass heparin significantly more
often than controls (adjusted odds ratio 17.33; 95% confi-
dence interval 3.71 to 80.95; p < 0.001). In addition, cases
used acetaminophen significantly more often than controls
(adjusted odds ratio 2.80; 95% confidence interval 1.64 to
4.79; p < 0.001). It is possible that these differences reflect in-
hospital treatment protocols rather than a true elevated risk for
serious NSAID ulcer complications. However, an increased
risk for NSAID ulcers with concomitant high-dose acetami-
nophen has been reported previously [13]. Exclusion of
patients with in-hospital NSAID ulcer complications truncated
the odds ratio for low-molecular-mass heparin (adjusted odds
ratio 6.06; 95% confidence interval 0.91 to 40.60; p = 0.06;
Table 5).
Cases reported a history of heart failure significantly more
often than controls (adjusted odds ratio 2.44; 95% confidence
interval 1.28 to 4.66; p = 0.007). The association between
heart failure and risk for NSAID-associated gastropathy has
previously been demonstrated, but a credible causational
mechanism remains to be identified [19].
One of the strengths of this study is that it reflects daily clinical
practice. The large randomised controlled clinical trials that
demonstrated the efficacy and safety of selective COX-2
inhibitors were conducted in relatively young, healthy subjects.
Our study suggests that these may not be the patients who are
especially at risk for serious NSAID ulcer complications and
confirms another recently conducted large nested case-con-
trol study that also found no evidence for enhanced gastroin-
testinal safety with selective COX-2 inhibitors [20]. Another
strength of our study lies in the robustness of the data. Gas-
trointestinal events in cases and controls were verified, as
were data on actual medication used. Other groups have stud-
ied populations of up to several thousand patients, but associ-
ations were derived by coupling databases and the validity of
the data was not always verified [21,22].
The local infrastructure makes it unlikely that many cases were
missed. However, one weakness of this study is that underes-
timation of the number of events might still have occurred.
Another weakness of this study, as in any case-control study,
is the possibility of selection bias. Although we have controlled
for all known possible confounders, selection by indication or
an unknown confounding mechanism cannot be excluded with
certainty.
Conclusion
Serious NSAID ulcer complications have a significant mortality
rate: 10.6% die in hospital and 14.4% within 3 months of the
event. At risk are especially elderly patients with cardiovascu-
lar co-morbidity. In daily clinical practice, the concomitant use
of PPIs is associated with a two-thirds reduction in the risk for
serious NSAID ulcer complications.
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